Research and Development

Showing 15 posts of 9594 posts found.

NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
Kadcyla

NICE says no to NHS funding for Kadcyla

December 16, 2015 Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer

NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …

Precious Cells Group appoints David Huse in expansion push

December 15, 2015 Medical Communications, Research and Development Stem cells, precious cells group

Precious Cells Group, a UK-based international provider of stem cell storage and related technologies, has announced the appointment of commercial …
amgen_hq

Amgen buys back rights to three drugs from GSK

December 15, 2015 Research and Development, Sales and Marketing Amgen, GSK

Amgen has announced that it will reacquire the rights to three products in 48 countries from GSK, as it seeks …

Bristol-Myers Squibb chooses UCLA as latest research partner

December 14, 2015 Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla

Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …
Ablynx CEO Edwin Moses

Ablynx sets focus on pharma collaborations

December 14, 2015 Manufacturing and Production, Research and Development Ablynx, collaboration, nanobodies, partnership

Drug development companies should prioritise strategic pharma collaborations to keep up with the next wave of immuno-oncology treatments, the chief …
halaven

Eisai’s Halaven shown to restrict further cancer metastasis

December 11, 2015 Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
roche_scientists

Which are pharma’s most innovative companies?

December 11, 2015 Medical Communications, Research and Development GSK, Roche, research and development

It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …
AZ_scientist

AstraZeneca deal to delve into the secretome

December 11, 2015 Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome

MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015 Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
xarelto

Regulators to probe Bayer’s Xarelto trial results

December 10, 2015 Medical Communications, Research and Development

Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …
Novolog pen

Novo Nordisk files for new insulin approval

December 10, 2015 Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
Merck researcher

Merck/Pfizer Alliance to collaborate on late-stage cancer trials

December 10, 2015 Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer

Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
Guido Rasi

EMA sets out new five-year plan

December 9, 2015 Research and Development EMA, Guido Rasi

The European Medicines Agency’s (EMA) new executive director, Professor Guido Rasi, outlined his vision for his five-year mandate at the …
healthy-human-t-cell_credit_celgene-web

Researchers launch CAR-T cell therapy trial in head and neck cancer

December 9, 2015 Research and Development CAR-T, CAR-T therapy, Cancer, head and neck cancers, oncology R&D

A pioneering trial is beginning in London, where doctors are harnessing patients’ own immune systems to find a new effective …
The Gateway to Local Adoption Series

Latest content